These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

401 related items for PubMed ID: 9049482

  • 1. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
    Rachman J, Barrow BA, Levy JC, Turner RC.
    Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
    [Abstract] [Full Text] [Related]

  • 2. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF, Edwards CM, Ghatei MA, Mather HM, Bloom SR.
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [Abstract] [Full Text] [Related]

  • 3. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J, Gribble FM, Barrow BA, Levy JC, Buchanan KD, Turner RC.
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T, Krarup T, Madsbad S, Holst JJ.
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [Abstract] [Full Text] [Related]

  • 6. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J.
    Regul Pept; 2005 Jun 15; 128(2):149-57. PubMed ID: 15780434
    [Abstract] [Full Text] [Related]

  • 7. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
    Hücking K, Kostic Z, Pox C, Ritzel R, Holst JJ, Schmiegel W, Nauck MA.
    Diabet Med; 2005 Apr 15; 22(4):470-6. PubMed ID: 15787675
    [Abstract] [Full Text] [Related]

  • 8. Overnight GLP-1 normalizes fasting but not daytime plasma glucose levels in NIDDM patients.
    Willms B, Idowu K, Holst JJ, Creutzfeldt W, Nauck MA.
    Exp Clin Endocrinol Diabetes; 1998 Apr 15; 106(2):103-7. PubMed ID: 9628239
    [Abstract] [Full Text] [Related]

  • 9. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA.
    Horm Metab Res; 2004 Apr 15; 36(11-12):852-8. PubMed ID: 15655719
    [Abstract] [Full Text] [Related]

  • 10. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.
    Toft-Nielsen MB, Madsbad S, Holst JJ.
    Diabetes Care; 1999 Jul 15; 22(7):1137-43. PubMed ID: 10388979
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
    Meier JJ, Gallwitz B, Salmen S, Goetze O, Holst JJ, Schmidt WE, Nauck MA.
    J Clin Endocrinol Metab; 2003 Jun 15; 88(6):2719-25. PubMed ID: 12788879
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
    Nauck MA, Meier JJ.
    Regul Pept; 2005 Jun 15; 128(2):135-48. PubMed ID: 15780433
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.